KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
about
Precision medicine in colorectal cancer: the molecular profile alters treatment strategiesKRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectivePerformance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experienceAllele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutationKRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessmentHybridization-Induced Aggregation Technology for Practical Clinical Testing: KRAS Mutation Detection in Lung and Colorectal Tumors.High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity.Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer.Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor.Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technologyFascin expression in colorectal carcinomas.Analysis and verification of the HMGB1 signaling pathway.A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinomaSensiScreen®KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations.Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.A comparability study of 5 commercial KRAS testsKRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies.Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencingKRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment.Targeting the EGFR signaling pathway in cancer therapy.KRAS and BRAF mutational status in colon cancer from Albanian patients.The role of oncogenes in gastrointestinal cancer.Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancerMonitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancerExternal quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancerRAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centresSomatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndromeTumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective.Thermodynamic framework to assess low abundance DNA mutation detection by hybridization.KRAS mutations and subtyping in colorectal cancer in Jordanian patients.A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas.Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer
P2860
Q26795558-E6E04685-E642-409E-9D1F-B45DEDBCAAEEQ27851532-5B14A3AA-9E30-4BB3-B32F-A1A89FAD6C24Q28070038-F1034112-ED47-4835-A2F1-0B0827760F7BQ28534874-4ACA3BC6-3900-4CAD-A63D-AF72F466ECA0Q28730199-E0C38260-8651-4471-B969-40E6775BEFF0Q28741021-179D5D9D-1789-4890-9E89-FDE83E7FA35CQ30276632-74141EC0-63C7-4853-BB68-70C7698C69B6Q33405398-175D69BF-2F9A-4D98-AE8E-FA81B6FB6212Q33493198-3ABFDEEB-07EE-49DD-B5C2-C68BF9AED600Q33510817-8EF013FD-A344-4BB8-B951-AD33FFCC1D66Q33514878-DD4DECD4-2699-4DBE-981F-AD16178870AFQ33587972-BB9165CC-10D0-46AE-8F4B-C8CE92C22EF3Q33684686-30650DFD-7C92-45C3-80A0-F812EADA9467Q33755561-F9D0C39D-5F39-41F9-B714-794EB7328957Q33813835-FCE0A9D9-C7C9-4B4F-9A97-A8B4B1DEE762Q33821751-66F3CAAE-99FF-48A3-928A-55FCF7CC5B6CQ33847505-3A55A5C9-0DB0-457A-A1AB-B62B0D7584C0Q33888034-A7958526-9CC5-4BEE-81DE-0CD486C5D026Q33983671-D7CCEECC-906F-4EE6-94E7-7BA53969776DQ34029615-BF121F23-B4CB-42A6-9D9F-9446C7A95886Q34142761-FBD57525-D4B7-4440-99BC-66727E825DF9Q34246558-269633D8-2432-4086-8815-79F3C114FB21Q34346064-04EEAFCE-494B-4735-89EC-E4D8829A918EQ34616409-D40338C3-5CF3-4962-A131-7E9AA34B63E1Q35076220-D80F8903-F3D1-4A58-AABF-9040C4ADE5ABQ35215449-8602BF09-87B5-46A2-BD67-CC2BF77CCAC8Q35374477-09523ACC-81C8-4450-8D4E-8DCF3917B813Q35460703-86B2915B-D963-466F-9826-A75DFFAB6136Q35584550-6536FBB1-07CD-495B-B557-3BED21AA30DFQ35760814-331D9228-E6BA-49D2-BBA3-89925391E779Q35962621-68109611-A011-4C6A-960D-7DC6EFAD7713Q36166765-A9389638-710E-44CD-9193-200976AD4DC9Q36175288-C68B7766-A67D-42A0-A94A-53D33D8F7FB4Q36190010-4523FB5C-8CF4-497C-A079-370BF34912D6Q36276146-941E32F6-4732-4E6F-BB7A-7984E02C9640Q36289392-20DF8FC5-ADF0-489C-9ECF-F7935F8FB056Q36380169-EB86ECFD-476A-4BA9-A2A1-54309382CDAFQ36424058-1B615855-3BD6-4C58-9D60-3E797FD308F0Q36523724-C12DD0D0-43E1-465D-9C00-F7DFD8BD0303Q36621776-35A82493-B5F5-48C8-923B-505AC0465B10
P2860
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
KRAS mutation testing for pred ...... ean quality assurance program.
@en
KRAS mutation testing for pred ...... ean quality assurance program.
@en-gb
KRAS mutation testing for pred ...... ean quality assurance program.
@nl
type
label
KRAS mutation testing for pred ...... ean quality assurance program.
@en
KRAS mutation testing for pred ...... ean quality assurance program.
@en-gb
KRAS mutation testing for pred ...... ean quality assurance program.
@nl
prefLabel
KRAS mutation testing for pred ...... ean quality assurance program.
@en
KRAS mutation testing for pred ...... ean quality assurance program.
@en-gb
KRAS mutation testing for pred ...... ean quality assurance program.
@nl
P2093
P2860
P50
P1433
P1476
KRAS mutation testing for pred ...... pean quality assurance program
@en
P2093
D Tiniakos
F T Bosman
G de Hertogh
J F Fléjou
J H J M van Krieken
M Ligtenberg
P2860
P2888
P304
P356
10.1007/S00428-008-0665-Y
P577
2008-09-18T00:00:00Z